Format

Send to

Choose Destination
Int Braz J Urol. 2003 Nov-Dec;29(6):517-9.

Complete response of metastatic renal cancer with dendritic cell vaccine.

Author information

1
Discipline of Urology, Paulista School of Medicine, Federal University of São Paulo, UNIFESP, Sírio Libanês Hospital of São Paulo and Department of Immunology, ICB-USP, São Paulo, SP, Brazil. marcosdalloglio@uol.com.br

Abstract

INTRODUCTION:

We report a case of metastatic renal cell carcinoma that presented involution following therapy with dendritic cells.

CASE REPORT:

Male, 51-year old patient underwent left radical nephrectomy in September 1999 due to renal cell carcinoma, evolved with recurrence of the neoplasia in January 2002, confirmed by resection of the lesion. A vaccine therapy based on dendritic cells was then performed during 5 months (4 applications). After this period, there was occurrence of new lesions, whose resection revealed areas of necrosis and inflammatory infiltrate.

DISCUSSION:

The outcome of renal cell carcinoma is influenced by prognostic factors that confer more aggressive tumor characteristics. However, in cases of recurrence, the systemic therapy with dendritic cells-based vaccine can be associated with a better outcome with regression of disease.

PMID:
15748305
Free full text

Supplemental Content

Full text links

Icon for International Braz J Urol
Loading ...
Support Center